Evidence map›Paper›PMID 33205581›Full record

ArticleESC heart failure2021

Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.

Krister Lindmark, Björn Pilebro, Torbjörn Sundström, Per Lindqvist

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05950867 (Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause), which is not on this map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05950867 narecruitingnot on this mapstarted 2023, after this paper: background citation

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)

TypeinterventionalSponsorUniversitair Ziekenhuis BrusselRan2023 to 2026Enrolled150ConditionsPolyneuropathy, AmyloidosisArmsECG + echocardiography, Answering questionnaires
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Wild-type Cardiac Amyloidosis due to Transthyretin Protein - A Review.Journal of community hospital internal medicine perspectives · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Article
  20. Echocardiographic red flags of ATTR cardiomyopathy a single centre validation.European heart journal. Imaging methods and practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Krister LindmarkHeart Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Björn PilebroHeart Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Torbjörn SundströmDiagnostic Radiology, Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Per LindqvistHeart Centre, Department of Surgery and Perioperative Sciences, Umeå University, Umeå, Sweden.
Umeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWild type transthyretin amyloidosis (ATTRwt) has gained interest during recent years due to better diagnostic tools and the emergence of treatment options. Little is known about the prevalence of the disease. We aimed to investigate the prevalence in a heart failure population with myocardial hypertrophy. METHODS AND

resultsAll patients with an ICD code of heart failure living within the catchment area of Umeå University hospital and intraventricular septum >14 mm were offered screening with 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan and a clinical work up. Out of 2238 patients with heart failure, 174 patients were found to have a septum >14 mm. Ten patients were already diagnosed with hereditary ATTR cardiomyopathy, 12 patients had ATTRwt cardiomyopathy, 12 patients had known HCM, one patient had AL amyloidosis, and four patients had already undergone a negative DPD scan (DPD uptake grade 0 and 1) within the last 3 years. This left 134 patients who we tried to contact for screening, but 48 patients had either died or declined to participate. Out of 86 screened patients, 13 had a DPD uptake of grade 2 or 3 without other amyloid disease making the total number of patients with ATTRwt in this population 25.

conclusionsApproximately 20% of investigated patients in a cohort with heart failure and increased myocardial wall thickness has ATTRwt. Calculated for the whole population of heart failure patients, the prevalence is just over 1.1%. Comparing this number to the total population would give an estimated prevalence of 1:6000.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesHeart FailureHumansPrevalenceRadionuclide ImagingAmyloidosisATTRwtCardiac amyloidosisHeart failureTransthyretin amyloidosis

Identifiers

PMID33205581
PMCPMC7835553
OpenAlexW3100624010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.